Liberate Medical
Liberate Medical is a clinical-stage medical device company developing neuromuscular electrical stimulation technology to improve respiratory care and patient outcomes. Their flagship product, VentFree, is a non-invasive neuromuscular electrical stimulator designed to prevent expiratory muscle atrophy in mechanically ventilated patients, aiming to reduce ventilation duration and improve clinical outcomes.
Industries
Nr. of Employees
small (1-50)
Liberate Medical
6400 Westwind Way, Suite A, Crestwood, KY 40014
Patents
Devices and methods for adjusting and tracking respiration-stimulating electrodes
US-12465763-B2
View Details
Devices and methods for adjusting and tracking respiration-stimulating electrodes
US-12465763-B2
View DetailsProducts
Respiratory muscle stimulator (non-invasive, breath-synchronized)
A medical device that delivers non-invasive electrical stimulation to expiratory/abdominal muscles synchronized with exhalation during mechanical ventilation, intended to prevent respiratory muscle atrophy and support weaning.
Respiratory muscle stimulator (non-invasive, breath-synchronized)
A medical device that delivers non-invasive electrical stimulation to expiratory/abdominal muscles synchronized with exhalation during mechanical ventilation, intended to prevent respiratory muscle atrophy and support weaning.
Services
Planning and operational support for randomized, sham-controlled, multi-center trials to evaluate device effectiveness in mechanically ventilated patients.
Provision of instructional videos and training materials covering electrode placement, flow sensor setup, titration, treatment workflow, troubleshooting and cleaning to support clinical adoption.
Planning and operational support for randomized, sham-controlled, multi-center trials to evaluate device effectiveness in mechanically ventilated patients.
Provision of instructional videos and training materials covering electrode placement, flow sensor setup, titration, treatment workflow, troubleshooting and cleaning to support clinical adoption.
Expertise Areas
- Respiratory muscle stimulation
- Ventilator weaning and liberation
- Clinical trial management for medical devices
- Regulatory strategy for medical devices (FDA, CE)
Key Technologies
- Non-invasive neuromuscular electrical stimulation
- Breath-synchronized stimulation (ventilator-timed)
- Ventilator flow-sensor integration
- Randomized, sham-controlled clinical trial methodology
News & Updates
Results from a pilot trial of VentFree Muscle Stimulator demonstrating feasibility and potential to reduce ventilator support duration in critically ill patients.
Announcement of the PREVENT clinical trial to demonstrate VentFree's effectiveness in reducing mechanical ventilation duration, supported by a $6.5M grant from the US Department of Defense.
Liberate Medical announced the successful closure of a $6.2M Series B financing round, co-led by a large strategic investor and Scientific Health Development, to support the pivotal clinical trial of VentFree.
A pilot trial demonstrated that VentFree may reduce ventilation duration and ICU stay, supporting its potential to improve outcomes.
The FDA authorized emergency use of VentFree to reduce disuse atrophy of abdominal muscles, potentially reducing ventilation days during the COVID-19 pandemic.
The CE marking indicates compliance with EU safety and performance standards, allowing sale within the European Economic Area.
Results from a pilot trial of VentFree Muscle Stimulator demonstrating feasibility and potential to reduce ventilator support duration in critically ill patients.
Announcement of the PREVENT clinical trial to demonstrate VentFree's effectiveness in reducing mechanical ventilation duration, supported by a $6.5M grant from the US Department of Defense.
Liberate Medical announced the successful closure of a $6.2M Series B financing round, co-led by a large strategic investor and Scientific Health Development, to support the pivotal clinical trial of VentFree.
A pilot trial demonstrated that VentFree may reduce ventilation duration and ICU stay, supporting its potential to improve outcomes.
The FDA authorized emergency use of VentFree to reduce disuse atrophy of abdominal muscles, potentially reducing ventilation days during the COVID-19 pandemic.
The CE marking indicates compliance with EU safety and performance standards, allowing sale within the European Economic Area.